Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Abdel Qader Al Bawab

Al-Zaytoonah University of Jordan, Amman, Jordan.

Title: Pharmacodynamics model of the effect of gliclazide therapy on Hemoglobin A1C in response in patients with type 2 diabetes

Biography

Biography: Abdel Qader Al Bawab

Abstract

Diabetes is a global health issue that affects more than 425 million people and is expected to affect over 690 million people by 2045. Because of its large propagation and related economic costs, diabetes is considered a main public health concern nationally and worldwide. Gliclazide (GLC) is a very commonly used oral hypoglycemic agent that is used in treatment of type 2 diabetes. As per the clinical treatment guidelines; GLC is considered as a second line treatment that is typically used concomitantly with metformin. Predictors to clinical outcome of using GLC (with metformin as a background therapy) is lacking. This study sheds the light of various predictors that are correlated to the effect of GLC on glycated hemoglobin (HbA1c) and facting plasma glucose (FPG).]